Assessment of the INVOcell Intravaginal Culture System

Paused · Not applicable

Conditions studied: Infertility

In brief

The INVOcell intravaginal culture system is a prescription device intended for preparing, holding, and transferring human gametes or embryos during intravaginal in vitro fertilization or intravaginal culture procedures. The original (FG-002) INVOcell culture system was FDA cleared through De Novo application (DEN150008). The purpose of this study is to evaluate the INVO Bioscience modified INVOcell system, comprised of the INVOcell Intravaginal Culture Device and Retention Device, in terms of the following: 2.1 Effectiveness of achieving fertilization, implantation, embryo development, clinical pregnancy, and live birth after 5-days of continuous vaginal incubation. 2.2 The comfort and retention of the INVOcell device and retention system intravaginally.

Key facts

Study ID

NCT04246268

Run by

INVO Bioscience, Inc.

People needed

180

Starts

2020-10-01

Expected to finish

2022-03-01

Last updated by the study team

2020-07-28

Who can join

Age: 18 and older, up to 37. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Women diagnosed with:
• Tubal factor
• Endometriosis (stage I or II)
• Ovulatory dysfunction
• Multiple female factors
• Males with mild male factor [mild male factor is defined as meaning: two or more semen analyses that have one or more variables which fall below the 5th centile as defined by the World Health Organization (WHO, 2010)]
• Couples with:
• Unexplained Infertility
• Multiple factors, of female and/or male origin
• The pre-selected couples will be included in the study only if they fulfill the more specific inclusion and exclusion criteria below:
• Couples may be included in the study only if they have been informed about the study and have given their written consent.
• Infertile couples with failure to conceive a diagnosed pregnancy after one year of unprotected intercourse (6 months if the woman's age is 35 years or more). This one-year requirement need not be fulfilled if oligomenorrhea or tubal factor is present, or donor sperm use is planned
• IVF has been determined by the physician to be their next appropriate treatment
• Women with desire for pregnancy using donor sperm will be eligible even absent infertility factors.
• Women included in the study should:
• Be between the age of 18 and 37 years (has not reached her 38th birthday at the time of enrollment).
• Have an anti-Müllerian hormone (AMH) level ≥ 0.8 ng/mL
• Have a normal uterine cavity as assessed in the past year by HSG, SHG or hysteroscopy. Prior tubal ligation is acceptable.
• Partner semen analysis within the past year must show a total of ≥ 15 million motile spermatozoa.

You may not qualify if…

• Inability to read and speak English fluently
• One (1) or more recurrent vaginitis or bacterial vaginosis (BV) requiring medical attention.
• A history of toxic shock syndrome
• Known allergies to plastic or silicone
• Had pelvic surgery within the past 8 weeks, excluding laparoscopy with or without salpingectomy (ies) or hysteroscopy with or without polypectomy
• Had pelvic inflammatory disease (PID) within the past 3 months and were treated with antibiotics
• Severe endometriosis (stage III-IV) or endometrioma(s) (past or present)
• Clinical signs of current vaginal infection
• Significant abnormalities of the vaginal cavity
• Submucous or intramural fibroids (>2 cm diameter)
• Hydrosalpinx
• Uncontrolled chronic illness, e.g. autoimmune disease, diabetes. Appropriately treated hypothyroidism, hypertension, dyslipidemia, e.g., are not exclusions.
• BMI >36.0 kg/m2
• Donor oocytes
• Antral follicle count (AFC; at cycle baseline) < 6
• Previously assessed as having a poor response to ovarian stimulation
• Patients with polycystic ovary syndrome (PCOS) meeting NIH (1990) criteria
• Cervical stenosis
• Recurrent pregnancy loss defined by recurrent non-biochemical pregnancy losses
• Failed fertilization of all oocytes obtained in a previous IVF cycle
• Smoke tobacco or vape, abuse drugs or alcohol
• Inability to understand or comply with trial procedures
• Partner with vasectomy reversal
• Partner with inability to produce sperm specimen
• Partner with uro-genital infection

Where it is running

• Piedmont Reproductive Endocrinology Group — Greenville, South Carolina, United States
• Piedmont Reproductive Endocrinology Group — West Columbia, South Carolina, United States
• Fertility Center of San Antonio — San Antonio, Texas, United States
• The New Hope Center for Reproductive Medicine — Virginia Beach, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.